Revolution Medicines slides as FDA review details uneven daraxonrasib responses by KRAS mutation
An FDA multi-discipline review showed daraxonrasib’s 32% response was stronger in G12V than G12D. RVMD dropped; Stifel keeps Buy.
An FDA multi-discipline review showed daraxonrasib’s 32% response was stronger in G12V than G12D. RVMD dropped; Stifel keeps Buy.
Lead candidate PRP demonstrated strong tumor control, reduced metastatic spread, and a 2.5-fold increase in survival in preclinical pancreatic cancer studies.
The FDA approved Revolution’s Rasonque, the first RAS-targeted daily pill for metastatic pancreatic cancer. It doubled median survival to 13.2 months, compared with 6.7 months with chemotherapy.
Erasca denies patent claims by Revolution Medicines, will fight back; Stifel keeps Buy rating.
New drug daraxonrasib from Revolution Medicines doubled survival in pancreatic cancer (13.2 vs 6.7 months) and cut death risk by 60% in Phase 3.
Jefferies initiates Buy on Design Therapeutics ($15 PT) & assumes coverage on Revolution Medicines ($140), Kymera ($110), Immatics ($18), Insmed ($228).